Andrew Cheng, President and CEO at Akero Therapeutics (NASDAQ:AKRO), reported a large exercise of company stock options on October 5, according to a new SEC filing.
What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Thursday showed that Cheng, President and CEO at Akero Therapeutics, a company in the Health Care sector, just exercised stock options worth 25,000 shares of AKRO stock with an exercise price of $6.36.
Akero Therapeutics shares are trading down 2.26% at $45.0 at the time of this writing on Thursday morning. Since the current price is $45.0, this makes Cheng's 25,000 shares worth $1,125,000.